SGP insider ownership: who sold, why, and what they still hold

What stands out

Two directors bought shares: Ali Behbahani (938K shares, $15.0M) and Bilal Khan (135K shares, $2.2M). These are the first purchases by current officers or directors in the filings on record.Ali Behbahani: purchase, Feb 9, 2026 · Bilal Khan: purchase, Feb 9, 2026

No officer or director sold shares in this period. 13 are left out

Left out: Malik Kahook, Patrick Mooney, Bilal Khan, James Dennewill Jr., Jean-Frederic Viret, Chetan Pujara, Elizabeth O'Farrell, Geoffrey Pardo, Kirk Nielsen, Zachary Scheiner, Michael Dybbs, Habib Dable and Ali Behbahani (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Feb 9, 20262 directors bought 1.07M shares ($17.2M).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Ali Behbahani Director	937,500	$16.00	n/a	n/a	Feb 9, 2026	Feb 11, 2026
Bilal Khan Director	135,000	$16.00	n/a	n/a	Feb 9, 2026	Feb 11, 2026

Outside holders, reported separately

RA CAPITAL MANAGEMENT, L.P., Mohamad Makhzoumi and Edward Mathers and 9 more reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the SpyGlass Pharma, Inc. CEO selling stock?

No. Patrick Mooney reported no open-market sales in the past 12 months.

Are any SpyGlass Pharma, Inc. insiders buying?

Yes. 2 officers or directors reported 3 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan

Board members representing outside shareholders, reported separately: Geoffrey Pardo, Kirk Nielsen. Details

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Mohamad Makhzoumi (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Edward Mathers (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: New Enterprise Associates 17, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Scott Sandell (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Paul Walker (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Anthony Florence Jr. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Carmen Chang (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Rick Yang (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Forest Baskett (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 13 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Malik Kahook

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Malik Kahook are complete.

President, Chief Medical Officer, Executive Chair, Director

n/a

Vesting, gifts, unvested awards and holding lines for Malik Kahook

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Malik Kahook are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
72,389	$2.18	Oct 5, 2033	$1.0M
191,874	$2.87	Apr 10, 2035	$2.5M
170,475	$7.11	Jul 23, 2035	$1.5M
105,000	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Patrick Mooney

Chief Executive Officer, Director

n/a

Vesting, gifts, unvested awards and holding lines for Patrick Mooney

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Patrick Mooney are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
112,803	$0.35	Jul 25, 2031	$1.8M
232,517	$2.18	Oct 5, 2033	$3.2M
105,536	$2.18	Dec 29, 2034	$1.5M
126,986	$2.87	Apr 10, 2035	$1.7M
329,784	$7.11	Jul 23, 2035	$2.9M
300,000	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Bilal Khan

Director

n/a

Vesting, gifts, unvested awards and holding lines for Bilal Khan

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bilal Khan are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,992	$2.18	Sep 19, 2033	$166K
48,533	$7.11	Aug 5, 2035	$431K
13,700	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

James Dennewill Jr.

Chief Operating Officer

n/a

Vesting, gifts, unvested awards and holding lines for James Dennewill Jr.

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Dennewill Jr. are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
78,494	$2.18	Oct 5, 2033	$1.1M
35,758	$2.87	Apr 10, 2035	$470K
54,745	$7.11	Jul 23, 2035	$487K
105,000	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Jean-Frederic Viret

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for Jean-Frederic Viret

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jean-Frederic Viret are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
263,907	$10.55	Nov 12, 2035	$1.4M
17,500	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Chetan Pujara

Chief R&D Officer

n/a

Vesting, gifts, unvested awards and holding lines for Chetan Pujara

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Chetan Pujara are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
153,219	$2.18	Feb 25, 2035	$2.1M
31,397	$2.87	Apr 10, 2035	$412K
34,798	$7.11	Jul 23, 2035	$309K
105,000	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Elizabeth O'Farrell

Director

n/a

Vesting, gifts, unvested awards and holding lines for Elizabeth O'Farrell

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Elizabeth O'Farrell are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
65,976	$7.11	Aug 5, 2035	$587K
13,700	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Geoffrey Pardo

Director

n/a

Vesting, gifts, unvested awards and holding lines for Geoffrey Pardo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Geoffrey Pardo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Kirk Nielsen

Director

n/a

Vesting, gifts, unvested awards and holding lines for Kirk Nielsen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kirk Nielsen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Zachary Scheiner

Director

n/a

Vesting, gifts, unvested awards and holding lines for Zachary Scheiner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Zachary Scheiner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Michael Dybbs

Director

n/a

Vesting, gifts, unvested awards and holding lines for Michael Dybbs

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Dybbs are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Habib Dable

Director

n/a

Vesting, gifts, unvested awards and holding lines for Habib Dable

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Habib Dable are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Ali Behbahani

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ali Behbahani

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ali Behbahani are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
27,400	$16.00	Feb 5, 2036	$0

Estimate: options held × ($16.00 − strike price), using the most recent insider trade price on Form 4 (Feb 9, 2026), not a market close.

Holdings and share of stake for SpyGlass Pharma, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Board members representing outside shareholders (2)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Geoffrey Pardo ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Geoffrey Pardo are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Geoffrey Pardo Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Geoffrey Pardo are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)
Kirk Nielsen ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kirk Nielsen are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Kirk Nielsen Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kirk Nielsen are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Known gaps and uncertainty13 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for SpyGlass Pharma, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology54 filings on record, 54 filed in the 12-month period, and how we read them

All 54 Forms 3, 4 and 5 on record for SpyGlass Pharma, Inc. (SEC CIK 1778922), filed from Feb 5, 2026 to Feb 11, 2026; 54 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

SpyGlass Pharma, Inc. insiders: what they own and what they did with it

What stands out

Recent activity

Outside holders, reported separately

Common questions

Is the SpyGlass Pharma, Inc. CEO selling stock?

Are any SpyGlass Pharma, Inc. insiders buying?

The evidence